Literature DB >> 11309319

Inhibitors of histone deacetylase are potentially effective anticancer agents.

P A Marks, R A Rifkind, V M Richon, R Breslow.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11309319

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  27 in total

1.  Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.

Authors:  Lucia Martiniova; Shiromi M Perera; Frederieke M Brouwers; Salvatore Alesci; Mones Abu-Asab; Amanda F Marvelle; Dale O Kiesewetter; David Thomasson; John C Morris; Richard Kvetnansky; Arthur S Tischler; James C Reynolds; Antonio Tito Fojo; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2011-01-13       Impact factor: 5.678

2.  Developmental exposure to valproic acid alters the expression of microRNAs involved in neurodevelopment in zebrafish.

Authors:  Neelakanteswar Aluru; Kristina L Deak; Matthew J Jenny; Mark E Hahn
Journal:  Neurotoxicol Teratol       Date:  2013-10-12       Impact factor: 3.763

3.  A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.

Authors:  Anish Thomas; Arun Rajan; Eva Szabo; Yusuke Tomita; Corey A Carter; Barbara Scepura; Ariel Lopez-Chavez; Min-Jung Lee; Christophe E Redon; Ari Frosch; Cody J Peer; Yuanbin Chen; Richard Piekarz; Seth M Steinberg; Jane B Trepel; William D Figg; David S Schrump; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2014-09-04       Impact factor: 12.531

4.  Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo.

Authors:  Amine Achachi; Arnaud Florins; Nicolas Gillet; Christophe Debacq; Patrice Urbain; Germain Manfouo Foutsop; Fabian Vandermeers; Agnieszka Jasik; Michal Reichert; Pierre Kerkhofs; Laurence Lagneaux; Arsène Burny; Richard Kettmann; Luc Willems
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-08       Impact factor: 11.205

5.  Inhibition of histone acetyltransferase by glycosaminoglycans.

Authors:  Jo Ann Buczek-Thomas; Edward Hsia; Celeste B Rich; Judith A Foster; Matthew A Nugent
Journal:  J Cell Biochem       Date:  2008-09-01       Impact factor: 4.429

6.  Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells.

Authors:  Priyanka Sharma; Santosh Kumar; Gopal C Kundu
Journal:  Mol Cancer       Date:  2010-07-07       Impact factor: 27.401

Review 7.  TRAIL gene therapy: from preclinical development to clinical application.

Authors:  Thomas S Griffith; Brittany Stokes; Tamara A Kucaba; James K Earel; Rebecca L VanOosten; Erik L Brincks; Lyse A Norian
Journal:  Curr Gene Ther       Date:  2009-02       Impact factor: 4.391

8.  Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.

Authors:  Pavan Reddy; Yoshinobu Maeda; Kevin Hotary; Chen Liu; Leonid L Reznikov; Charles A Dinarello; James L M Ferrara
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-04       Impact factor: 11.205

Review 9.  Epigenetics in bladder cancer.

Authors:  Hideki Enokida; Masayuki Nakagawa
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

10.  Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.

Authors:  S M Pulukuri; B Gorantla; J A Knost; J S Rao
Journal:  Oncogene       Date:  2009-06-08       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.